- Conditions
- Heart Failure, Congestive, Dyspnea, Pulmonary Edema
- Interventions
- Nesiritide
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 2,509
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ischemic Stroke, Stroke, Acute
- Interventions
- Tenecteplase, Control
- Drug · Other
- Lead sponsor
- University Hospital of North Norway
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan
- Other · Radiation · Drug + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2007
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Bevacizumab, Biopsy, Ipilimumab, Laboratory Biomarker Analysis, Metastasectomy, Nivolumab, Therapeutic Conventional Surgery
- Biological · Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Endometriosis, Infertility
- Interventions
- Leuprolide acetate in depot suspension, No intervention
- Drug · Other
- Lead sponsor
- Colorado Center for Reproductive Medicine
- Other
- Eligibility
- 21 Years to 42 Years · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Lone Tree, Colorado
- Conditions
- Graft Versus Host Disease
- Interventions
- stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Lichen Planus
- Interventions
- Etanercept, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 12
- States / cities
- Stanford, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
- Conditions
- Obese, Normal Body Weight, Prediabetes, Metabolic Syndrome
- Interventions
- Fat biopsy, Propranolol and fat biopsy, heavy water and fat biopsy
- Procedure · Drug · Other
- Lead sponsor
- Philip Kern
- Other
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Vesico-Ureteral Reflux
- Interventions
- OPTISON
- Drug
- Lead sponsor
- Kassa Darge
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cirrhosis, Ascites Hepatic
- Interventions
- Terlipressin acetate continuous infusion
- Drug
- Lead sponsor
- BioVie Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1994
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, goserelin, mitoxantrone hydrochloride, prednisone
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 983 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2018
- U.S. locations
- 234
- States / cities
- Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 157 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Acthar
- Drug
- Lead sponsor
- OhioHealth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome (MDS)
- Interventions
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
- Drug · Other · Radiation + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Portland, Oregon • Seattle, Washington
- Conditions
- Septic Shock
- Interventions
- Vasopressin, Recommendation to use a lower initiation threshold for vasopressin, Recommendation to use a higher initiation threshold for vasopressin
- Drug · Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,959 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Burley, Idaho • American Fork, Utah • Cedar City, Utah + 10 more
- Conditions
- Sarcoma
- Interventions
- graft versus host disease prophylaxis/therapy, busulfan, melphalan, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
- Interventions
- Leuprolide
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 7 Years to 18 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Etoposide, Ifosfamide, Lenalidomide, Positron Emission Tomography, Tafasitamab
- Procedure · Drug · Biological
- Lead sponsor
- David Bond, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Interventions
- filgrastim, carboplatin, etoposide, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Buffalo, New York • Houston, Texas
- Conditions
- Ischemic Stroke
- Interventions
- Aspirin, tinzaparin sodium, eptifibatide
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Liver Transplantation
- Interventions
- Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Overactive Bladder
- Interventions
- botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U)
- Biological · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Middlebury, Connecticut
- Conditions
- Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
- Interventions
- Angiotensin II and hydrocortisone sodium succinate
- Drug
- Lead sponsor
- Kingman Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Kingman, Arizona